MarginsXMarginsX
Home › Markets › Health Care › ADCT

ADC Therapeutics SA Common Shares (ADCT)

ADCT trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.25
-6.72% on the day
Market cap
$159.7M
Micro cap
Revenue · 2025
$81.4M
+14.9% on 2024
Net income · 2025
-$142.6M
-175.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1771910/000162828026016491/0001628280-26-016491-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerADCT on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySwitzerland
IPO year2020
SEC CIK0001771910
SEC industry codePharmaceutical Preparations
Incorporated inSwitzerland

Financials · 2025

LineValue
Revenue$81.4M
Net income-$142.6M
Operating income-$121.5M
Net margin-175.3%
Operating margin-149.3%
Revenue growth+14.9%
Cash$261.3M
Total assets$323.1M
P/E (computed)Net income was not positive
P/S (computed)2.0×

Warning signs

Cash runway
22.6 months
$189.2M cash at September 30, 2026
Share count, 1 year
+13.5%
2025-08-01 to 2026-08-03
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$19.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$189.2M cash; operating cash flow -$25.1M a quarter.Report 2026-09-30
Shares outstanding127,667,695 (2026-08-03); 112,499,395 a year earlier.Cover page 2026-08-03
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers AG, Lausanne, SwitzerlandPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $19.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$21.7M-$25.3M-$27.9M$189.2M$7.8M$84.9M10-Q 2026-11-09
Q2 2026
2026-06-30
$19.2M-$16.6M-$11.8M$219.1M$6.2M$79.6M10-Q 2026-08-13
Q1 2026
2026-03-31
$20.9M-$33.0M-$29.7M$231.0M$4.6M$79.2M10-Q 2026-05-04
Q4 2025
2025-12-31
$23.1M-$6.4M-$31.1M$261.3M$3.0M$81.4M10-K 2026-03-10
Q3 2025
2025-09-30
$16.4M-$41.0M-$29.6M$234.7MNo debt tags$75.2M10-Q 2026-11-09
Q2 2025
2025-06-30
$18.8M-$56.6M-$24.1M$264.6MNo debt tags$77.2M10-Q 2026-08-13
Q1 2025
2025-03-31
$23.0M-$38.6M-$56.3M$194.7MNo debt tags$75.8M10-Q 2026-05-04
Q4 2024
2024-12-31
$16.9M-$30.7M-$21.9M$250.9M$0$70.8M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32026-11-10
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxy
FORM DEFA14A
DEFA14A2026-04-20

Source: SEC EDGAR submissions feed, 442 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.2%
1 month-21.2%
3 months+27.6%
Year to date-62.0%
1 year-66.9%
From 52-week high-72.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$1.98-7.48%$158.9M
ZNTLZentalis Pharmaceuticals Inc.$1.60-5.88%$157.2M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier